Loading

logo

Journal of Rehabilitation Research and Practice

ISSN: 2694-0388

Case Report Open Access
Volume 5 | Issue 1 | DOI: https://doi.org/10.46439/rehabilitation.5.031

Cell therapy with autologous mesenchymal stem cells for premature baby with neonatal sepsis and bronchopulmonary dysplasia: Case report

Margarita G. Devyaltovskaya1, Dzmitry Sankavec1, Dariy Y. Nikitchanka1, Michael P. Potapnev2,*, Natalia V. Petyovka2, Alexander S. Voytehovich2
  • 1State Institution The Republican Scientific and Practical Center «Mother and Child», Minsk, 220083, Belarus
  • 2State Institution «Republican Center for Transfusiology and Medical Biotechnologies», Ministry of Health the Republic of Belarus, Minsk, 220080, Belarus
+ Affiliations - Affiliations

Corresponding Author

Michael P. Potapnev, mpotapnev@yandex.by

Received Date: July 29, 2024

Accepted Date: September 05, 2024

Citation:

Devyaltovskaya MG, Sankavec D, Nikitchanka DY, Potapnev MP, Petyovka NV, Voytehovich AS. Cell therapy with autologous mesenchymal stem cells for premature baby with neonatal sepsis and bronchopulmonary dysplasia: Case report. J Rehabil Res Pract. 2024;5(1):33-36.


Copyright: © 2024 Devyaltovskaya MG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Mesenchymal stem cells (MSCs) have significant regenerative and anti-inflammatory potential; therefore they are widely used in medical practice. Neonatology is becoming a new area of clinical application of MSCs, including pathology treatment of premature newborns. 
Objective: In the presented case report are demonstrated the results of cell therapy of bronchopulmonary dysplasia (BPD) with autologous MSCs in premature newborns who have suffered from neonatal sepsis. 
Methods: The patient was conducted with two intravenous injections of biomedical cellular product (BMCP) "Human mesenchymal stem cells” in addition to standard treatment.
Results: The presented clinical case demonstrates the effectiveness of autologous umbilical cord MSCs in the medical prevention of severe forms of BPD. The immunomodulatory effect of umbilical cord MSCs provided a favorable outcome of early onset neonatal sepsis (EONS). 
Conclusion: The inclusion of autologous MSCs in the therapy of premature babies with neonatal sepsis and developing BPD is a safe and effective treatment.

Keywords

Mesenchymal stem cells, Neonatal sepsis, Bronchopulmonary dysplasia, Newborn

Recommended Articles

Cell therapy with autologous mesenchymal stem cells for premature baby with neonatal sepsis and bronchopulmonary dysplasia: Case report

Bronchopulmonary dysplasia (BPD) remains the most common disease in premature newborns, associated with immature lung injury under the influence of supplemental oxygen and mechanical ventilation. “Classical BPD” is observed in premature newborns who have not received surfactant treatments. It is characterized by pulmonary fibrosis due to oxygen toxicity and volumetric/barometric trauma caused by mechanical ventilation. A new or "mild" form of BPD is observed in children born at 29 weeks of gestation, and is characterized by disordered pulmonary development due to prematurity.

Pulmonary agenesis in a newborn

There are all transitions from hypoplasia of the lung to agenesis or aplasia of a lung lobe and to complete absence of the entire lung system as classifies such malformations as follows: a) unilateral complete absence of lung and bronchus, b) absence of one half of the lung and a short blind course of the associated bronchus, c) trunk bronchus formed, lung as a hazelnut- to fist-sized, unflap fist- sized, unlobed, fleshy structure in the mediastinum.

Full Text
Cite
Download PDF
Author Information X